Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test could reveal hidden brain changes years before Alzheimer's symptoms

NCT ID NCT06023446

Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses a safe, painless eye scan called OCT to look at support cells (glia) in the retina, which is part of the brain. Researchers want to see if these cells work differently in people with early signs of Alzheimer's compared to those without. If they find a difference, it could lead to a new early screening test and help develop treatments that target glial health. About 100 participants with mild cognitive impairment or normal thinking will be scanned in light and darkness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward a new way to detect Alzheimer's early and suggest that targeting glial cells might lead to future treatments.
What could go wrong
This is an early observational study with only 100 participants. It does not test a treatment, so it may not lead to any direct benefit. Results may not apply to all people with Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators plan to recruit participants from: * Participants (or prospective participants) in research on aging and cognition at the University of California - Davis. * Patients (or prospective patients) of University of California - Davis neurologists.

Ages

50 to 89 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * By clinician (or prior research) assessment, known to either be cognitively normal, or have mild cognitive impairment * Known Alzheimer's biomarker status. As of 2023-JUL, this must either be an amyloid PET scan, or cerebrospinal fluid measurement of amyloid and tau levels. * NOTE: Although this is a study of the eyes, age-typical ocular/vision complaints are permissible, so long as the the retina is thought to be healthy. This list of acceptable conditions includes most people who: * wear glasses * wear contacts * use over-the-counter eye drops * have mild cataracts (no surgery scheduled) * had cataracts removed * had eye muscle surgery (e.g., to correct eye misalignment) * had eyelid surgery (blepharoplasty) * are monitored by an ophthalmologist in case a problem with the retina develops (this is sometimes suggested for people with diabetes), but one or both retinas is/are thought to be completely healthy Exclusion Criteria: * Pregnant women * Prisoners * Known \*for both eyes\* to have ocular health or vision abnormalities that are not age-typical. The list of unacceptable conditions includes most people who: * have a special corrective lens (glasses or contact lens) prescription with a sphere greater than seven * currently use prescription eye drops (e.g., for glaucoma) * have/had prior surgical treatment for a retinal problem (e.g., retinal detachment that required surgery) * have/had eye injections for age-related macular degeneration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Mild cognitive impairment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California - Davis

    Sacramento, California, 95816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.